Ignite Creation Date:
2025-12-18 @ 9:25 AM
Ignite Modification Date:
2025-12-23 @ 10:31 PM
Study NCT ID:
NCT03302247
Status:
None
Last Update Posted:
2020-10-28 00:00:00
First Post:
2017-09-27 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Sponsor:
None
Organization:
Study Overview
Official Title:
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
Status:
None
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Unable to accrue subjects
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary Objective
• The primary objective of this proposal is to evaluate gemcitabine as a method of MDSC depletion.
Secondary Objectives
* Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number.
* Determine the tolerability and clinical activity (including response rate and survival) of this approach.
* Correlate MDSC number with tumor PD-L1 expression
• The primary objective of this proposal is to evaluate gemcitabine as a method of MDSC depletion.
Secondary Objectives
* Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number.
* Determine the tolerability and clinical activity (including response rate and survival) of this approach.
* Correlate MDSC number with tumor PD-L1 expression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: